Growth Hormone & PerformanceGrade B
Sermorelin
A GHRH (1-29) analog historically approved for diagnostic GH testing and pediatric growth hormone deficiency.
- Regulatory status
- Previously FDA approved (withdrawn commercially)
- Half-life
- ~10–20 minutes
- Route
- Subcutaneous, before bed
- Evidence
- Limited human trials or approved outside the US
Mechanism of action
Stimulates endogenous GH release via pituitary GHRH receptors.
Studied and reported uses
- GH deficiency evaluation
- Age-related GH decline protocols
Dosing information
Common range200–500 mcg nightly
Cycle3–6 months with IGF-1 monitoring
Ranges are reported from literature and clinical labeling for reference only. They are not a dosing recommendation.
Side effects
- Injection-site reaction
- Flushing
- Headache
- Dizziness
Research evidence
Pediatric trials
Improved growth velocity in GHD children.